image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 1.15
-5.65 %
$ 228 M
Market Cap
-1.38
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one ESPR stock under the worst case scenario is HIDDEN Compared to the current market price of 1.15 USD, Esperion Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one ESPR stock under the base case scenario is HIDDEN Compared to the current market price of 1.15 USD, Esperion Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one ESPR stock under the best case scenario is HIDDEN Compared to the current market price of 1.15 USD, Esperion Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ESPR

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
332 M REVENUE
185.66%
54.4 M OPERATING INCOME
134.97%
-51.7 M NET INCOME
75.27%
-23.7 M OPERATING CASH FLOW
82.54%
-317 K INVESTING CASH FLOW
-0.75%
86.5 M FINANCING CASH FLOW
71.39%
65 M REVENUE
-5.96%
-22.1 M OPERATING INCOME
-399.91%
-40.5 M NET INCOME
-89.77%
-22.6 M OPERATING CASH FLOW
35.26%
0 INVESTING CASH FLOW
0.00%
-7.5 M FINANCING CASH FLOW
-21.43%
Balance Sheet Esperion Therapeutics, Inc.
image
Current Assets 338 M
Cash & Short-Term Investments 145 M
Receivables 80.1 M
Other Current Assets 113 M
Non-Current Assets 5.82 M
Long-Term Investments 0
PP&E 5.77 M
Other Non-Current Assets 56 K
42.10 %23.31 %32.89 %Total Assets$343.8m
Current Liabilities 246 M
Accounts Payable 51.6 M
Short-Term Debt 54.6 M
Other Current Liabilities 140 M
Non-Current Liabilities 486 M
Long-Term Debt 243 M
Other Non-Current Liabilities 243 M
7.05 %7.45 %19.11 %33.15 %33.23 %Total Liabilities$732.5m
EFFICIENCY
Earnings Waterfall Esperion Therapeutics, Inc.
image
Revenue 332 M
Cost Of Revenue 68.6 M
Gross Profit 264 M
Operating Expenses 209 M
Operating Income 54.4 M
Other Expenses 106 M
Net Income -51.7 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)332m(69m)264m(209m)54m(106m)(52m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
79.36% GROSS MARGIN
79.36%
16.37% OPERATING MARGIN
16.37%
-15.57% NET MARGIN
-15.57%
13.31% ROE
13.31%
-15.05% ROA
-15.05%
35.75% ROIC
35.75%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Esperion Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -51.7 M
Depreciation & Amortization 63 K
Capital Expenditures -317 K
Stock-Based Compensation 12 M
Change in Working Capital 0
Others 76.6 M
Free Cash Flow -24 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Esperion Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for ESPR of $12 , with forecasts ranging from a low of $8 to a high of $20 .
ESPR Lowest Price Target Wall Street Target
8 USD 595.65%
ESPR Average Price Target Wall Street Target
12 USD 943.48%
ESPR Highest Price Target Wall Street Target
20 USD 1639.13%
Price
Max Price Target
Min Price Target
Average Price Target
2020181816161414121210108866442200Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Esperion Therapeutics, Inc.
image
Sold
0-3 MONTHS
51 K USD 3
3-6 MONTHS
29.1 K USD 3
6-9 MONTHS
44.9 K USD 3
9-12 MONTHS
33.9 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Esperion Appoints Craig Thompson to Board of Directors Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience globenewswire.com - 3 weeks ago
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Management projects profitability by Q1 2026, but I am wary given current revenue, cash, and expense guidance—profitability claims seem optimistic without a clear revenue boost. Pipeline developments, including a triple-combo LDL-C pill and liver/kidney therapies, could be transformative, but near-term catalysts hinge on execution and proof of profitability. seekingalpha.com - 1 month ago
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. globenewswire.com - 2 months ago
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET. globenewswire.com - 2 months ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. globenewswire.com - 2 months ago
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada – Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to commercialize NEXLETOL* and NEXLIZET* in Canada. globenewswire.com - 2 months ago
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. zacks.com - 2 months ago
Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Jason Zemansky - Bank of America Kristen Kluska - Cantor Fitzgerald Jessica Fye - J.P. seekingalpha.com - 2 months ago
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago. zacks.com - 2 months ago
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Esperion to Participate in The Citizens Life Sciences Conference ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. globenewswire.com - 2 months ago
8. Profile Summary

Esperion Therapeutics, Inc. ESPR

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 228 M
Dividend Yield 0.00%
Description Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Contact 3891 Ranchero Drive, Ann Arbor, MI, 48108 https://www.esperion.com
IPO Date June 26, 2013
Employees 304
Officers Mr. Sheldon L. Koenig President, Chief Executive Officer & Director Mr. Benjamin Halladay M.B.A. Chief Financial Officer Mr. Glenn P. Brame Chief Technical Operations Officer Dr. Stephen Pinkosky Vice President of Drug Discovery of Early Pre-Clinical Development Tiffany Aldrich M.B.A. Associate Director of Corporate Communications Ms. Betty Jean Swartz Chief Business Officer Mr. Benjamin O. Looker J.D. General Counsel & Corporate Secretary